János Fodor1, Tibor Major1, József Tóth2, Zoltán Sulyok3, Csaba Polgár1. 1. Department of Radiotherapy, National Institute of Oncology, Ráth Gy. u. 7-9, Budapest H-1122, Hungary. 2. Department of Pathology, National Institute of Oncology, Budapest, Hungary. 3. Department of Surgery, National Institute of Oncology, Budapest, Hungary.
Abstract
BACKGROUND: Invasive lobular cancer (ILC) is biologically distinct from invasive ductal cancer and there is disagreement regarding appropriate local management of this disease. AIM: The current study reports long term results comparing mastectomy with breast-conserving surgery (BCS) in the treatment of ILC. MATERIAL AND METHODS: Study includes 235 women with ILC treated between 1983 and 1987. All of them underwent axillary dissection and either mastectomy (n = 163) or BCS (n = 72). 50 Gy adjuvant radiotherapy (RT) was given for 53 BCS and 81 mastectomy patients. The BCS group was compared with the mastectomy group. RESULTS: Patients treated with mastectomy or BCS had a similar outcome at 15 years with regard to distant metastasis-free (62% vs. 70%; p, 0.2017) and breast cancer-specific (62% vs. 70%; p, 0.1728) survival. In the BCS group the actuarial rate of ipsilateral in breast recurrences was 10% with and 53% without RT at 15 years (relative risk [RR], 0.10; p < 0.0001). In the mastectomy group the actuarial rate of chest wall recurrences was 16% with and 13% without RT at 15 years (RR, 1.45; p, 0.3965). Isolated ipsilateral in breast recurrence did not (RR, 1.73; p, 0.2767) but isolated chest-wall recurrence did (RR, 2.65; p, 0.0089) adversely affect cause-specific survival. CONCLUSION: Breast cancer specific survival is not affected by the type of surgical treatment. BCS and RT is a safe option to control local disease in patients with ILC.
BACKGROUND: Invasive lobular cancer (ILC) is biologically distinct from invasive ductal cancer and there is disagreement regarding appropriate local management of this disease. AIM: The current study reports long term results comparing mastectomy with breast-conserving surgery (BCS) in the treatment of ILC. MATERIAL AND METHODS: Study includes 235 women with ILC treated between 1983 and 1987. All of them underwent axillary dissection and either mastectomy (n = 163) or BCS (n = 72). 50 Gy adjuvant radiotherapy (RT) was given for 53 BCS and 81 mastectomy patients. The BCS group was compared with the mastectomy group. RESULTS:Patients treated with mastectomy or BCS had a similar outcome at 15 years with regard to distant metastasis-free (62% vs. 70%; p, 0.2017) and breast cancer-specific (62% vs. 70%; p, 0.1728) survival. In the BCS group the actuarial rate of ipsilateral in breast recurrences was 10% with and 53% without RT at 15 years (relative risk [RR], 0.10; p < 0.0001). In the mastectomy group the actuarial rate of chest wall recurrences was 16% with and 13% without RT at 15 years (RR, 1.45; p, 0.3965). Isolated ipsilateral in breast recurrence did not (RR, 1.73; p, 0.2767) but isolated chest-wall recurrence did (RR, 2.65; p, 0.0089) adversely affect cause-specific survival. CONCLUSION:Breast cancer specific survival is not affected by the type of surgical treatment. BCS and RT is a safe option to control local disease in patients with ILC.
Entities:
Keywords:
Breast-conserving therapy; Invasive lobular breast cancer; Mastectomy
Authors: M Bouvet; D W Ollila; K K Hunt; G V Babiera; F R Spitz; A E Giuliano; E A Strom; F C Ames; M I Ross; S E Singletary Journal: Ann Surg Oncol Date: 1997-12 Impact factor: 5.344
Authors: T P Mate; D Carter; D B Fischer; P V Hartman; C McKhann; M Merino; L R Prosnitz; J B Weissberg Journal: Cancer Date: 1986-11-01 Impact factor: 6.860
Authors: J M Kurtz; J Jacquemier; J Torhorst; J M Spitalier; R Amalric; R Hünig; E Walther; F Harder; A Almendral; H Brandone Journal: Cancer Date: 1989-04-15 Impact factor: 6.860
Authors: M S Anscher; P Jones; L R Prosnitz; W Blackstock; M Hebert; R Reddick; A Tucker; R Dodge; G Leight; J D Iglehart Journal: Ann Surg Date: 1993-07 Impact factor: 12.969
Authors: X Sastre-Garau; M Jouve; B Asselain; A Vincent-Salomon; P Beuzeboc; T Dorval; J C Durand; A Fourquet; P Pouillart Journal: Cancer Date: 1996-01-01 Impact factor: 6.860
Authors: Anita Mamtani; Emily C Zabor; Laura H Rosenberger; Michelle Stempel; Mary L Gemignani; Monica Morrow Journal: Ann Surg Oncol Date: 2019-08-27 Impact factor: 5.344
Authors: Sadia Tasleem; Jarlath C Bolger; Michael E Kelly; Michael R Boland; Dermot Bowden; Karl J Sweeney; Carmel Malone Journal: Ir J Med Sci Date: 2018-02-01 Impact factor: 1.568
Authors: Jun Su Park; Doo Ho Choi; Seung Jae Huh; Won Park; Young Il Kim; Seok Jin Nam; Jeong Eon Lee; Won Ho Kil Journal: J Breast Cancer Date: 2015-09-24 Impact factor: 3.588
Authors: Mary Kathryn Abel; Case E Brabham; Ruby Guo; Kelly Fahrner-Scott; Jasmine Wong; Michael Alvarado; Cheryl Ewing; Laura J Esserman; Rita A Mukhtar Journal: Am J Surg Date: 2020-06-19 Impact factor: 2.565